Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ERCC4
REST API REST API
Homo sapiens
ERCC4 is differentially expressed in 242 experiments: 92 organism parts: bone marrow, blood, ... (90 more);, 132 disease states: normal, breast carcinoma, ... (130 more);, 66 cell types 251 cell lines 35 compound treatments and 73 other conditions.
Synonyms XPF, RAD1
Orthologs RAD1 (Saccharomyces cerevisiae)   Q5ZJP8_CHICK (Gallus gallus)   LOC688631 (Rattus norvegicus)   ercc4 (Danio rerio)   Ercc4 (Rattus norvegicus)   D3ZNM4_RAT (Rattus norvegicus)   Ercc4 (Mus musculus)   ENSCING00000005673 (Ciona intestinalis)   ERCC4 (Bos taurus)   mei-9 (Drosophila melanogaster)   ercc4 (Xenopus laevis)   ERCC4 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term response to UV, chromosome, telomeric region, telomere maintenance, DNA binding, double-strand break repair via homologous recombination, nucleotide-excision repair, protein binding, DNA repair, nuclease activity, damaged DNA binding, protein N-terminus binding, nucleic acid binding, single-stranded DNA binding, nuclear chromosome, telomeric region, meiotic mismatch repair, nucleus, endodeoxyribonuclease activity, resolution of meiotic recombination intermediates, hydrolase activity, endonuclease activity, protein C-terminus binding, nucleoplasm, DNA metabolic process, nucleotide-excision repair, DNA incision, telomere maintenance via telomere shortening, transcription-coupled nucleotide-excision repair, negative regulation of telomere maintenance, nucleotide-excision repair complex, structure-specific DNA binding, UV protection, nucleotide-excision repair, DNA incision, 3'-to lesion, nucleotide-excision repair, DNA incision, 5'-to lesion, single-stranded DNA specific endodeoxyribonuclease activity, nucleotide-excision repair factor 1 complex, nucleotide-excision repair, DNA damage removal
InterPro Term ERCC4_domain, Rad1
Gene-Disease Assocation XFE PROGEROID SYNDROME, XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP F; XPF
UniProt Accession Q92889, B4DXD8, E7ETX4, F8W7K7
Search EB-eye ENSG00000175595
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-MTAB-24, E-MTAB-25, ... (21 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-4525, E-GEOD-19639, E-GEOD-2450, E-MTAB-62, ... (28 experiments)

Factor Value U/D Experiments
MCF-7
2
E-GEOD-19639, E-GEOD-20081
MOLT4
2
E-MTAB-37, E-MTAB-62
SW480
2
E-MEXP-1014, E-MTAB-37
MDA-MB-231
1
2
E-TABM-420, E-MTAB-62, E-GEOD-5823
RPMI 8226
1
E-MEXP-921
A204
1
1
E-MTAB-37
245 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-GEOD-13909, ... (35 experiments)

Factor Value U/D Experiments
M1 macrophage
1
E-GEOD-5099
PBMCs
1
E-GEOD-20677
BDCA4+ dentritic cell
1
E-TABM-145
liver cancer
1
E-GEOD-21154
leydig cell
1
E-MTAB-25
CD34+
1
E-TABM-145
60 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-2466, E-MEXP-2069, E-GEOD-22148, ... (45 experiments)

Factor Value U/D Experiments
prostate carcinoma
2
E-MEXP-2034, E-MTAB-62
extranodal NK/T-cell lymphoma
1
E-GEOD-19067
idiopathic dilated cardiomyopathy
1
E-GEOD-1145
none
1
E-GEOD-21610
iatrogenic Kaposis sarcoma, KSHV-
1
E-MEXP-66
papillary thyroid carcinoma
1
E-GEOD-3467
126 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-GEOD-697, E-TABM-782, E-GEOD-5824, ... (25 experiments)

Factor Value U/D Experiments
none
4
8
E-GEOD-5824, E-TABM-782, E-GEOD-412, E-GEOD-7307, E-TABM-868, ... (12 experiments)
lipopolysaccharide
2
E-TABM-868, E-MEXP-1958
phenol
1
E-GEOD-6907
AMP
1
1
E-MEXP-2285
estradiol
1
E-GEOD-20081
unknown
1
E-GEOD-7307
29 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
tunicamycin
1
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-860, E-GEOD-1563, ... (8 experiments)

Clinical treatment
studied in E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-20033, E-GEOD-2666, E-GEOD-4667, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-GEOD-21138, E-GEOD-1751

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-4086

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, ... (7 experiments)

Genotype
studied in E-GEOD-2466, E-GEOD-17476, E-TABM-321, E-TABM-601, E-GEOD-1153 ... (5 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-MEXP-2657, E-TABM-127, E-MEXP-1446, ... (10 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

immunoprecipitated protein
studied in E-GEOD-21918

Individual
studied in E-TABM-325, E-MTAB-197, E-MEXP-2069, E-GEOD-1926, E-MEXP-1648, ... (32 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-980, E-GEOD-17400 ... (5 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

Organism
studied in E-AFMX-1, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-22309, E-GEOD-17636

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-15811, E-GEOD-18791, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-101, E-GEOD-3697, E-MEXP-1857, E-MEXP-2759

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400, E-GEOD-18995

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-19246, E-GEOD-15799

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Vehicle
studied in E-GEOD-5258

Processing time: 0.318 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM